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Abstract: The International Society of Urological Pathology
(ISUP) organized a Consultation Conference in March 2019
dealing with applications of molecular pathology in Urogenital
Pathology, including testicular tumors (with a focus on germ cell
tumors [GCTs]), preceded by a survey among its members to get
insight into current practices in testicular germ cell tumor (TGCT)
diagnostics and adoption of the ISUP immunohistochemical guide-
lines published in 2014. On the basis of the premeeting survey, the
most commonly used immunomarker panel includes OCT3/4, pla-
cental alkaline phosphate, D2-40, SALL4, CD117, and CD30 for
GCTs and the documentation of germ cell neoplasia in situ (GCNIS).
Molecular testing, specifically 12p copy gain, is informative to dis-
tinguish non-GCNIS versus GCNIS related GCTs, and establishing
germ cell origin of tumors both in the context of primary and meta-
static lesions. Other molecular methodologies currently available but
not widely utilized for TGCTs include genome-wide and targeted
approaches for specific genetic anomalies, P53 mutations, genomic
MDM2 amplification, and detection of the p53 inactivating miR-
371a-3p. The latter also holds promise as a serum marker for malig-
nant TGCTs. This manuscript provides an update on the classification
of TGCTs, and describes the current and future role of molecular-
genetic testing. The following recommendations are made: (1) Presence
of GCNIS should be documented in all cases along with extent of
spermatogenesis; (2) Immunohistochemical staining is optional in the
following scenarios: identification of GCNIS, distinguishing embry-
onal carcinoma from seminoma, confirming presence of yolk sac tu-
mor and/or choriocarcinoma, and differentiating spermatocytic tumor
from potential mimics; (3) Detection of gain of the short arm of
chromosome 12 is diagnostic to differentiate between non-GCNIS
versus GCNIS related GCTs and supportive to the germ cell origin of
both primary and metastatic tumors.
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Testicular germ cell tumors (TGCTs) represent a highlyheterogenous group of neoplasms, including both benign
and malignant, displaying a tremendous variety of morpho-
logic elements in pure or mixed forms. On the basis of clinical
evidence through various independent confirmatory and mul-
tidisciplinary studies, the proposal for a novel GCT classi-
fication was accepted at the last Consensus meeting of the
World Health Organization (WHO) held in 2015, providing
the basis for the new WHO classification (2016).1,2 The most
crucial change was the replacement of the nomenclature of
intratubular germ cell neoplasia of unclassified type (IGCNU)
by germ cell neoplasia in situ (GCNIS), which allowed re-
classification of TGCTs in 2 fundamentally different categories:
GCNIS associated and non-GCNIS associated TGCTs
(Fig. 1). This was a remarkable departure from the former
WHO classification and also provided a platform for the
potential construction of a molecular/genetic classification.
Most malignant TGCTs (type II tumors) originate from
GCNIS. In contrast, non–GCNIS-related TGCTs encompass,
in fact, 2 distinct types, being the prepubertal-type teratomas/
yolk sac tumors (YSTs) (type I) and spermatocytic tumors
(type III) because of different cells of origin and pathogenesis.
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Recognition of this fundamentally and conceptually
different classification system provided an opportunity to
identify novel biomarkers for primary (testicular) diag-
nosis and metastatic or relapsed lesions. It is relevant to
indicate that these biomarkers are also informative for
ovarian as well as extragonadal GCTs (including media-
stinal and sacrococcygeal).
The International Society of Urological Pathology
(ISUP) recently organized a Consultation Conference
dealing with applications of molecular pathology in Ur-
ogenital Pathology, including testicular tumors (heavily fo-
cused on TGCTs), preceded by a survey among its members
to get insight in current practice and relevant application of
molecular methodologies. The members of the testicular
working group were identified based on their expertise in the
testicular pathology and association with major diagnostic
centers. The survey questions were developed after input from
the ISUP working group (which also solicited input from
Dr Thomas Ulbright from Indiana University for which we
are greatly appreciative of his valuable suggestions and in-
sight). After the survey results were collated, the members of
the testis working group, with the editorial oversight of ISUP
genitourinary experts, came up with the recommendations
based on survey results, prior ISUP recommendations, and
panel members’ diagnostic expertise. This manuscript pro-
vides an updated review of TGCT classification and its ra-
tionale, describes the current and potential future role of
molecular-genetic testing, and discusses evidence and chal-
lenges to utilize currently available molecular-genetic tests.
Recommendations are provided to practicing pathologists in
light of existing evidence, survey results and expert feedback.
Since the role of immunohistochemistry (IHC) in the diag-
nosis of various TGCTs is crucial due to prognostic im-
plications and clinical decision making, the implementation
and effectiveness of the ISUP IHC guidelines developed from
a similar survey in 2014 was also investigated.
ISUP SURVEY RESULTS FOR TESTICULAR
TUMORS
The survey results are as follows. A total of 256 mem-
bers of ISUP responded to one or more questions of the survey
(Supplementary Table, Supplemental Digital Content 1, http://
links.lww.com/PAS/A911). Only 17% of 208 respondents
processed >50 orchiectomy specimens per year, while 12%
evaluated <10 orchiectomies per year.
FIGURE 1. Schematic representation of the various entities of TGCTs. The timeline is indicated on the left side. The TGCTs include the
non-GCNIS related TGCTs (left panel) and GCNIS-related TGCTs (right panel). The non-GCNIS related TGCTs are subcategorized into
the prepubertal TE (being diploid) and YST as well as the spermatocytic tumors. These are also referred to as type I and III, respectively.
The GCNIS-related TGCTs are histologically (and clinically) subdivided into the seminomas (SE) and the various elements of non-
seminomatous TGCTs, being embryonal carcinoma (EC), YST, choriocarcinoma, and TE. Note the overlapping histology between the
prepubertal TE/YST and the TE and YST elements in the GCNIS-related nonseminomas (being underlined). However, they have a
separate (and independent) pathogenesis (see text for further details). The precursors are indicated when known (preinvasive), while
specifically, the benign and malignant behavior of the pediatric TE and YST is highlighted. Besides, the most prominent and recurrent
molecular genetic changes are indicated, of putative interest to be used for molecular pathologic approaches. These include total
genomic anomalies, like polyploid/aneuploid, specific chromosomal imbalances like losses (−), and gains (+), as well; as recurrent
mutations (italics). Also, the methylation status is indicated, as well as the possible use of miR-371a-3p as a liquid biopsy molecular
biomarker (underlined). All malignant histologic elements, independent of age, are identified by this biomarker (except TE). The WNT
pathway is specifically involved in the YST components, independent of age and as such also of pathogenesis.
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IHC Survey Results and Discussion
Among 207 respondents, 32% routinely used (> 80%
of cases) IHC for diagnosis of TGCT, while only 5% never
used IHC for this purpose. In total, 47% of respondents
applied the IHC recommendations based on the previous
ISUP consultation paper authored by Ulbright et al.3 The
remaining either did not use or were not aware of them.
Overall, 70% of respondents used IHC for documentation
of GCNIS in testicular biopsy using OCT3/4, placental
alkaline phosphatase (PLAP), D2-40 (podoplanin),
SALL4, and cKIT (CD117), sometimes in combination.
OCT3/4 was the most commonly used IHC for doc-
umentation of GCNIS (69%). In orchiectomy specimens,
49% utilized IHC for documentation of GCNIS, again
OCT3/4 being the most popular biomarker (68%).
In light of the survey results and for the reader’s interest,
it is imperative to discuss the role and utilization of IHC stains
in the differential diagnosis of TGCTs. A commentary is
provided, incorporating the survey results and discussing the
use of different IHC markers as outlined in a previously
published ISUP article in addition to any recent updates.3
OCT3/4 (POU5F1) is the most popular marker used in
the identification of GCNIS, especially in biopsy material.
Other markers including PLAP, D2-40 (podoplanin), SALL4,
and cKIT (CD117), are less commonly used (Supplementary
Table, Supplemental Digital Content 1, http://links.lww.com/
PAS/A911). OCT3/4 has been shown to be 100% sensitive in
seminomas, embryonal carcinomas, and GCNIS, and it is
perceived as a gatekeeper in developing an algorithm for the
differential diagnosis of TGCTs.4,5 In addition to GCNIS
recognition, its expression narrows the differential diagnosis
only to seminoma and embryonal carcinoma, which can be
further resolved by a number of IHC markers routinely
available in most laboratories. CD117 and CD30 are most
helpful in discerning between seminoma and embryonal carci-
noma. CD117 is virtually expressed in all seminomas (and
GCNIS) while negative in embryonal carcinoma.6 CD30 is
positive in embryonal carcinoma (up to100%) but negative in
seminoma.6 Other markers, including podoplanin and SOX17,
are expressed in seminoma but are negative in embryonal
carcinoma.7,8 AE1/AE3 and SOX2 are positive in embryonal
carcinoma while negative in seminoma.7
OCT3/4 negative TGCTs include YST, choriocarcino-
ma, and spermatocytic tumor. A limited panel including gly-
pican 3 (GPC3), alpha-fetoprotein (AFP), β-human chorionic
gonadotropin (hCG), and possibly PLAP is most helpful for
the distinction of these tumors. GPC3 is a sensitive marker for
YST; however, its expression may be observed in up to 80% of
choriocarcinomas.9 AFP is specific for YST, but it is less sen-
sitive and often expressed focally when compared with
GPC3.10 β-hCG is sensitive for choriocarcinoma but may be
expressed in other nontrophoblastic tumors.11,12 PLAP has an
overall limited role in germ cell tumor (GCT) distinction as it
can be variably positive in most GCTs.13 PLAP has fallen out
of favor with the increasing availability of overall more sensi-
tive and specific GCT markers such as OCT3/4 and GPC3.
Spermatocytic tumor is negative for all the commonly used
germ cell markers except CD117, which can be positive in
~40% of tumors, and is a potential pitfall for misdiagnosis as a
seminoma; the lack of OCT3/4 expression can be useful in
differentiating between spermatocytic tumor and semi-
noma.13,14
Overall, the subtyping of TGCTs can be achieved by
using a limited panel of markers including OCT3/4, CD117,
CD30, and GPC3, keeping in mind the potential pitfalls that
may be prevented with a careful examination of morpho-
logic features. It is needless to say that morphologic findings
alone are sufficient in most cases and IHC should only be
utilized in challenging cases. Altered morphology is com-
monly a result of poor specimen fixation.15
In rare instances, the differential diagnosis involves a sex
cord stromal tumor. In this setting, SALL4 can be utilized to
rule out TGCTs by virtue of its expression in most cases and is
particularly useful in TGCT metastases. 16 Sterogenic factor-
1, α-inhibin, and calretinin can further aid in establishing the
diagnosis. If SALL4 is not available, an alternate panel may
be used including OCT4, GPC3, α-inhibin, and calretinin.
SALL4 is also helpful in discerning other rare tumors
occuring in the testis such as lymphomas or metastatic carci-
nomas from TGCTs. Hematopoietic markers markers, in-
cluding CD45, CD20, and CD3, should be included in the
initial panel for this differential diagnosis. In the setting of
possible metastatic carcinoma, SALL4, OCT3/4, and EMA or,
alternatively, OCT4, GPC3, EMA, and CK7may be helpful in
the distinction. Other immunostains may be indicated de-
pending on the mophologic features of the tumor, such as
PAX8 (for renal primary) or NKX3.1 (for prostate primary).
In summary, appropriate use of IHC stains may aid in
the correct subclassification of testicular tumors and it is
recommended that OCT3/4, GPC3, and SALL4 should be
acquired by the laboratories that often deal with GCTs in
their practices. The recommendations presented in previous
IHC survey article are still valid; adherence and proper uti-
lization of these recommendations is fundamental in pro-
viding accurate diagnosis and best practices in pathology.
Molecular Testing Survey Results and Discussion
Among 206 respondents, an overwhelming majority
(71%) answered that they never obtained molecular/genetic
testing results on testicular specimens either requested by
physicians or ordered by the pathologists themselves, while
molecular-genetic testing was performed occasionally or rarely
by 24% and 5%, respectively (Supplemental Table, Supple-
mental Digital Content 1, http://links.lww.com/PAS/A911).
The presence of 12p gain, often in the form of isochromosome
12p (i(12p)) was the most common (77% of those who ordered)
testing performed for testicular specimens. Targeted genome-
wide mutational profiling, microsatellite instability analyses,
and genome-wide DNA copy number variation (CNV) mo-
lecular testing were performed in the frequency of 7.5%, 2.5%,
and 2%, respectively. None of the participants ordered micro-
RNA profiling for clinical use.
Most commonly, i(12p) analysis was performed to
confirm TGCT origin in metastatic tumors, especially those
with somatic type differentiation and to differentiate between
prepubertal versus postpubertal type teratoma. Fluorescent
in situ hybridization (FISH) testing was utilized by at least 73%
of the respondents who requested testing. Other methodologies,
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including Oncoscan/single nucleotide polymorphism (SNP)
array, next-generation sequencing, and molecular biology, were
utilized less frequently. Another 8.6% of respondents who sent
molecular testing to reference laboratories did not specify their
methodology. More than two thirds of the FISH testing was
performed in house while the remaining was done at outside
laboratories or in reference centers.
Targeted gene wide mutational profiling was performed
in cases with a differential diagnosis of sex cord-stromal tu-
mor, determination of chemoresistance, to identify targetable
genes, comprehensive molecular testing, and testing with a
cancer hot spot panel or for research purpose. Microsatellite
instability analysis was most commonly done by IHC and less
often by other methodologies, particularly in the context of
metastatic disease.
When asked about the context of the overall use of
molecular testing, the most common indication was to
confirm GCNIS and GCNIS derived tumors via gain of
12p. The other indications in the descending order were
metastatic TGCT, mutational therapy, unknown malig-
nancy, recurrent TGCT, and gene profiling.
In the next paragraphs, a comprehensive summary
of the various types of TGCTs will be presented, with the
focus on their cell of origin and early pathogenetic
changes, possibly resulting in targets for molecular testing.
NON–GCNIS-RELATED (TYPES I AND III)
TESTICULAR GCTS
Non–GCNIS-related TGCTs encompass prepubertal-
type teratomas and/or prepubertal-type YST (type I TGCT),
predominantly diagnosed at early (pediatric) age, and sper-
matocytic tumor (type III TGCT), always diagnosed after
puberty. Both non-GCNIS (type 1 TGCT, benign) related
teratoma and GCNIS related teratomas (type II TGCT, with
malignant potential) may occur in the pediatric age group, and
for this reason, it is recommended that the terms prepubertal-
type teratoma and postpubertal-type teratoma should be used
respectively.17 Similarly, a prepubertal-type teratoma may
rarely occur in an adult, thought to represent a persistent le-
sion from an earlier age.
YSTs are malignant, independent of whether type I or
type II, though type I may have a low incidence of
progression.18 There is no established cell of origin for pre-
pubertal-type testicular teratoma/YST, but an early embry-
onic germ or stem cell has been proposed as a possible
candidate.19,20 The other non–GCNIS-related TGCT is
spermatocytic tumor (previously spermatocytic seminoma)
(type III TGCT). The nomenclature of the current WHO
2016 classification was adopted to give this entity a distinct
label separating it from seminoma and highlight its indolent
behavior. There is abundant evidence that spermatocytic
tumors originate from a more mature germ cell phenotype,
likely a spermatogonium or spermatocyte.
The presence of GCNIS implies a (potentially) ma-
lignant type II TGCT. In the case of only atrophic semi-
niferous tubules, the absence of GCNIS must be
interpreted with caution. However, IHC is vital to confirm
absence of GCNIS in this situation and classification of
type I teratoma. In difficult cases, investigation of the
genomic composition (ie, diploid vs. aneuploid) of the ter-
atoma is much more informative. By virtue of its metastatic
potential, the presence of a YST in association with teratoma
becomes the major predictor of its behavior.21 The presence
of seminoma, embryonal carcinoma, or choriocarcinoma
will establish the diagnosis of GCNIS derived TGCT (type
II) and will dictate the clinical management accordingly (see
Fig. 1 for decision making). No IHC stain is available to
differentiate between a prepubertal-type or postpubertal-type
teratoma/YST. In the clinical setting, presence of GCNIS,
and evaluation of the molecular genetic composition is more
informative for this distinction.
Molecular Genetic Constitution
No recurrent somatic mutations are identified so far
in prepubertal teratomas,22–24 including DEAD-END, as a
candidate gene from mouse studies.25 Although the pedia-
tric teratomas are diploid, aneuploidy is characteristic for
pediatric YSTs, showing a specific pattern of imbalances
(chromosome 1 [gain], 6q [loss], and part of 12p [gain, in
particularly 12p13]).24,26 Possible candidate genes might be
STELLA, NANOG, and GDF3, being important in the
context of FISH data analyses to differentiate between a
non–GCNIS-related and GCNIS-related YST.27,28 Besides
FISH, evaluation of broad CNVs can be diagnostic as well.
Besides gain of (a part of) the short arm of chromosome 12,
6q loss is also characteristic for GCNIS-related YSTs, in-
dicating that it is linked to yolk sac differentiation.29,30
Specific CNV can also be detected using other ap-
proaches, amongst other polymerase chain reaction based as-
says, SNP-based or DNA methylation-based arrays.17,31–33 Of
interest is that a selection of germline SNPs is linked to the
formation of pediatric (including testicular) GCTs. They are, in
fact, susceptibility alleles, possibly playing a role in their
pathogenesis in addition to environmental factors.34,35 Up to
now, no genome-wide studies on somatic mutations have been
performed, limiting the comparison to the other types of
GCTs.36–38 A summary is presented in (Fig. 2 Aa–c and Ba–h).
Recommendations
Non–GCNIS-related TGCTs should be distinguished
from the GCNIS-related ones, in which the absence (or pres-
ence) of GCNIS in the background is a helpful feature, and its
presence may be confirmed using IHC for OCT3/4. FISH for
12p gain should be performed to facilitate the diagnosis of a
prepubertal-type teratoma in postpubertal patients. Non–
GCNIS-related (benign) teratomas (type I) are diploid with-
out specific genetic anomalies.
SPERMATOCYTIC TUMORS (TYPE III
TESTICULAR GCTS)
The spermatocytic (type III) TGCTs are now renamed
as “spermatocytic tumor” in the WHO 2016 classification
system, predominantly occurring in elderly men with rare
exceptions in younger males. Their distinct pathogenesis has
been recently elucidated in great detail.39–46 The proposed cell
of origin is either a spermatogonium or early primary sper-
matocyte, based on their cellular composition, RNA, and
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FIGURE 2. A, Microscopic example of a prepubertal pure testicular teratoma (3 y of age) (a, b, hematoxylin & eosin [H&E]) after
enucleation to leave the testis function intact (top panel). No GCNIS was demonstrated in the adjacent parenchyma. Also, no
chromosomal imbalances were identified using EPIC methylation profiling, transferred to CNV (lower panel) (c); B, Example of a
pure prepubertal YST (YST) (7mo of age) macroscopically (a) as well as microscopically (b, c, H&E) and IHC for AFP (d). A mixed
GCT displaying prepubertal YST admixed with teratoma component in a 4 months old boy (e, f, H&E). Note immature semi-
niferous tubules without GCNIS or active spermatogenesis (f). GPC3 highlighted the YST component (g). The chromosomal
imbalances are determined based on EPIC methylation profiling data, showing loss of 1p and 6q (right lower panel) (h).
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protein profiles. Microscopically these tumors are composed
of a polymorphous population of cells with 3 distinct cell types
being small, intermediate, and large. Intratubular growth is
common, and GCNIS is absent (Fig. 3). Clinically, sperma-
tocytic tumors are indolent unless sarcomatoid transformation
is present.47–50 The primary differential diagnosis is with
seminoma, which has a characteristic immune profile quite
different from spermatocytic tumor, as previously discussed. A
number of proteins may potentially be useful for the diagnosis
of spermatocytic tumors, but not currently used in the clinical
setting, include XPA, CYP1, SSX2-4, DMRT1,51 CHK2, P53,
p16INK4d, MAGE-4A,52 OCT2, SAGE1,53 NUT, GAGE7,
and NY-ESO-12.45 In addition, the absence of OCT3/4 is
informative to distinguish it from seminoma.
Molecular Genetic Constitution
Spermatocytic tumors display a unique chromosomal
pattern of gains and losses40–42,44,46,54,55 in comparison to the
other types of TGCT with gain of chromosome 9 present in
all cases investigated. DMRT1 overexpression,56 mapped on
chromosome 9, is likely related to the consistent gain of this
chromosome in spermatocytic tumors. Also, these tumors
lack recurrent chromosomal breaks, although they can also
show loss of chromosome 7.44,46 No somatic mutations have
been reported, with the exception of HRAS and FGFR3.
The latter are of specific interest because they are also found
in spermatogenesis of elderly males, involved in the process
known as “selfish spermatogonial selection” favoring
expansion of mutated germ cells and rendering germs cells in
the offspring of older fathers prone to acquire de novo
mutations44,57–59 (see below and Fig. 3).
Recommendations
Spermatocytic tumor is almost always recognizable
by morphology alone. IHC can help in challenging cases
with unusual morphology, keeping in mind the potential
pitfall of CD117 expression (misinterpretation as semi-
noma) but its lack of OCT3/4 reacitivity.
GCNIS-RELATED TESTICULAR GCTS: TYPE II—
HISTOLOGIC DIVERSITY AND CELL OF ORIGIN
GCNIS,2 the precursor lesion of all GCNIS-related
TGCTs (also referred to as type II TGCTs) was previously
referred to as carcinoma in situ,60 IGCNU, or testicular in-
tratubular neoplasia61 (Fig. 4). The latest 2016 WHO
terminology reflects the nature and pathogenesis of these
lesions. GCNIS cells represent a totipotential embryonic germ
cell (ie, primordial germ cells/gonocytes) capable of generating
all embryological differentiation lineages, including somatic
(teratoma, including all 3 germ layers) and extraembryonic
(YST and choriocarcinoma). Moreover, initiation of formation
of the earliest precursors of germ cell lineage itself can be found
in nonseminomas,62 representing the circle of life in full
perspective, that is, demonstrating its omnipotent character.








FIGURE 3. Examples of a spermatocytic tumor, macroscopically (A, B), and microscopically (hematoxylin & eosin [H&E]) (C, D),
and IHC for DMRT1 (E), and direct alkaline phosphatase (dAP) (G). Macroscopically, the tumor appears homogenous on cut
surface, whitish to yellow-tan nodular neoplasm replacing the testicular parenchyma, possibly multifocal. Note the unique pres-
ence of 3 variants of cells, being small, intermediate, and large. The precursor, known as intratubular spermatocytic tumor, is
shown (D). Also, spectral karyotyping (SKY) (F) and array comparative genomic hybridization are shown (H), demonstrated gain of
the whole chromosome 9.41
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summarized in Table 1, and representative examples are given
in Figure 4. Supplementary Table 1 (Supplemental Digital
Content 1, http://links.lww.com/PAS/A911) summarizes the
informative proteins to identify the different histologic elements
of invasive GCTs, of which representative examples for semi-
noma and embryonal carcinoma in Figure 5 (being SOX17
and SOX2, in combination with OCT3/4, for seminoma and
embryonal carcinoma, respectively) and discussed above in
IHC section.63 Furthermore, we refer our readers to the series
of papers written by ISUP expert panels regarding appropriate
IHC utilization for genitourinary tumors, including testicular
tumors.64
Molecular Genetic Constitution
Most invasive GCNIS-related TGCTs have over-
representation of 12p, predominantly as isochromosomes
i(12p).65–69 It is absent in GCNIS, and therefore likely required
for Sertoli cell-independent survival70 (Fig. 6). Seminomas can
show high-level amplification of specific subregions of
12, including KRAS.68,73–76 Some GCNIS-related GCTs,
mostly seminomas, appear to lack a gain of 12p,32,77 possibly
indicating an alternative pathway (with preferential cKIT
mutations). It is thought that GCNIS cells without gain of 12p
or cKIT mutations will not progress further to invasive
GCT. The 12p anomalies can be demonstrated by various
approaches, including (FISH), SNP array, as well as
methylation array (450K or EPIC platform).28,30,31,65,68,74,76,78
Several mutational studies,79–82 including the most ex-
tensive series investigated by the The Cancer Genome Atlas
(TCGA) initiative reported by Shen et al,77 demonstrate a low
mutational burden in TGCT type II independent of histology
with only about ~0.1 to 0.5 somatic changes per Mb. This is in
the same range as found in pediatric (non-GCNIS) cancer and
spermatocytic tumors (type III). CNV and mutational status
analyses indicate that, like for spermatocytic tumors (see
above); also 2 variants of seminomas do exist, that is one with
and another without KIT mutations, possibly related to the
overall level of genome methylation, and gain of 12p.
Other mutations or amplification relate to only KRAS,












FIGURE 4. Representative examples of GCNIS and gonadoblastoma. GCNIS (top 2 rows) (postpubertal patient with an invasive
GCT) stained using hematoxylin & eosin (H&E) (A) and IHC for TSPY (B), OCT3/4 (C), KITLG (D), SOX9 (sertoli cell marker, lower
magnification) (E), as well as direct alkaline phosphatase (dAP) (F); Gonadoblastoma (lower row) stained using H&E (G) and IHC for
OCT3/4 (H), and (I) FOXL2 (granulosa cell marker). Inset represents the complete overview of the sample slide, the higher
magnification area is indicated in the red box.
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KITLG in nonseminomas is relevant in the context of
the assumed cKIT-KITLG loop, either autocrine or para-
crine, involved in the earliest stage of pathogenesis.85 The
identification of amplification ofMDM2 is interesting because
of the previously reported involvement of the P53/MDM2
axis in therapy resistance.86,87 Other putative targets
TABLE 1. ISUP Recommendations for Reporting and Molecular Testing Related to Testicular GCTs
Topics Recommendations Remarks
Application of IHC for final diagnosis
GCT, and presence of GCNIS in
biopsy and orchiectomy specimen
1. Presence of GCNIS must be documented, both in case
of biopsy and orchiectomy
1. Reporting extent of spermatogenesis is highly
recommended. Absence of testicular parenchyma as
well as complete lack of spermatogenesis (ie, germ
cells) must be specified
2. IHC is informative to identify GCNIS (ie, using
OCT3/4)
2. IHC for OCT3/4 is suboptimal in case of Stieve and
Bouin fixatives
3. Seminoma and embryonal carcinoma can be further
distinguished based on supplemental IHC biomarkers
in difficult cases (ie, poor fixation)
3. IHC for OCT3/4 and SOX17 (for seminoma) and
OCT3/4, CD30, and SOX2 (embryonal carcinoma).
Lymphovascular invasion by embryonal carcinoma
is of relevance for risk stratification of stage 1
nonseminomas
4. Overdiagnosis of GCNIS in prepubertal testis (first
few years of life) may be avoided using OCT3/4
staining
4. Morphologic characterization related to specific
localization and clonal expansion can be
informative, as well as IHC for TSPY and KITLG
5. Presence of GB must be checked for, especially in
case of nonscrotal testis, and seemingly presence of
intratubular seminoma (mimicking GB)
5. GB is diagnostic for DSD, implicating GCT risk of
contralateral gonad (testis?). IHC for FOXL2
(granulosa cells) is informative (compared with
SOX9 of Sertoli cells)
6. Spermatocytic tumor is almost always
recognizable via morphology alone; difficult cases
can be distinguished using absence of staining for
IHC markers typically positive in mimics
6. Spermatocytic tumor is in principle benign with
exception of sarcomatous transformation; bilateral
cases do occur
7. IHC for AFP/GPC3 and β-hCG is helpful in
confirming presence of YST and choriocarcinoma,
respectively
7. No differential diagnostic IHC biomarkers are
known for non-GCNIS and GCNIS related YST.
Nonchoriocarcinomatous trophoblastic tumors must
be considered in DD
8. SALL4 can be used as surrogate marker for GCT,
especially in the setting of unknown history or
unusual morphology in metastasis
8. SALL4 is nonspecific and should be interpreted with
caution as other non-germ cell tumors may be
positive
Performance of molecular testing 1. Molecular testing is informative to distinguish non-
GCNIS vs. GCNIS related GCTs (primary and
metastatic)
1. Precaution has to be taken to include sufficient
amount of tumor cells in the final analyses
performed
2. Non-GCNIS related (benign) teratomas (type I) are
diploid without specific genetic anomalies. This can be
detected using (F)ISH, qPCR, as well as other more
genome wide approaches ((array) CGH, SNP array,
methylation arrays (450K or EPIC)
2. Enucleation can be considered in case of absence of
GCNIS and a diploid DNA content. Genome wide
approaches (see under 3) are most informative;
intraoperative consultation may be helpful
3. Gain of (the entire) 12p, on top of an overall
aneuploid DNA content, is characteristic for most
GCNIS related GCTs, both seminomas and
nonseminomas, although not for GCNIS itself
(although being aneuploid). This can be detected using
the techniques mentioned under point 3
3. Genome wide approaches are more informative
than a single target-based method
4. P53 mutations or genomic MDM2 amplification
seem to be the most prominent changes related to
treatment resistance of GCNIS related GCT so far.
MSI seems to be of limited value. Possibly tumor
heterogeneity must be kept in mind
4. Interference with this pathway might be an
interesting approach to follow. Again, tumor
organoids might be informative
5. Gain of the entire chromosome 9 is characteristic for
spermatocytic tumor. This can be detected using the
techniques mentioned under point 3
5. Genome wide CNV distinguished seminoma from
spermatocytic tumor
6. cKIT, KRAS, HRAS, and PI3CA are the most
frequent mutations, especially found in seminoma
(mainly without 12p)
6. Interference with this pathway might be an
interesting approach to follow
7. miR-371a-3p (and related family members) is
informative to detect malignant GCT components,
including YST of the non-GCNIS variant (type I). It
can be detected both in tissue as well as body fluids
(ie, liquid biopsies)
7. Efforts must be performed to prove the value of this
molecular test compared with the golden standard
AFP and hCG to promote clinical implementation.
Liquid biopsy will likely find its usefulness in recent
future
Bold indicates the most relevant in clinical practice at this moment.
CGH, comparative genomic hybridization; DD, differential diagnosis; DSD, disorder of sex development; GB, gonadoblastoma; hCG, human chorionic gonadotropin;
MSI, microsatellite instability; qPCR, quantitative polymerase chain reaction.
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(ie, RAC1 and FAT1) for potential targeted therapy have
been reported in limited cases.88,89 Although one study related
microsatellite instability to cisplatin resistance,90 this was not
confirmed in another larger series investigated, possibly due to
the selection of predominantly treatment sensitive cases.77 The
single report on matched GCNIS and invasive nonseminoma
elements demonstrated that although the precursor is aneu-









FIGURE 5. Representative example of a mixed germ cell tumor composed of seminoma and embryonal carcinoma (and a small
teratoma component and GCNIS [not shown]) (patient 25 y of age) macroscopically (A), stained using hematoxylin & eosin (H&E)
(B) and IHC for OCT3/4 (C), TSPY (D), SOX17 (highlighting seminoma) (E) and SOX2 (highlighting embryonal carcinoma) (F). No
double-positive cells for SOX2 and SOX17 are identified, while all are positive for OCT3/4.
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were found in the precursors.70 This, on the other hand,
strongly suggests that mutational load (although low) is pro-
gression related.
The resulting model is that GCNIS-related TGCTs
are developmental cancers with a disturbed micro-
environment. Possibly alterations in the supportive sertoli
cells results in a flawed niche inappropriate for full ma-
turation of embryonic germ cells.19,20,91–99
Recommendations
IHC stains may be useful in distinguishing between
the different subtypes of malignant TGCTs. Appropriate
panels should be selected after the differential diagnosis has
been narrowed down to 2 possible entities with careful
evaluation of the tumor morphology. Molecular testing is
helpful to distinguish between non-GCNIS versus GCNIS
related TGCTs, in both primary and metastatic settings, via
identification of 12p alterations.
APPLICATION OF miR-371a-3p AS MOLECULAR
BIOMARKER FOR MALIGNANT GCTS IN LIQUID
BIOPSIES
The first report on the putative impact of miR-371a-3p
as a potential molecular biomarker for GCTs in 2006100
showed that members of the miR-371-3 family could act as
an alternative mechanism for P53 inactivation, resulting in
overruling of cellular senescence. This was recently confirmed
for all miR-371-3 family members.101 High throughput
and targeted analyses showed that miR-371a-3p is expressed
explicitly in all malignant components of TGCTs, either being
type I or II.102–104 The molecule was detectable in serum,
plasma, and cerebrospinal fluids of patients with malignant
TGCT as well as in relevant preclinical models.105–117 During
adult life, miR-371a-3p is also expressed by normal sper-
matogonia.118 The data available in literature so far show
convincingly that miR-371a-3p as molecular liquid biopsy
TGCT biomarker is more informative compared with the
golden standard AFP and hCG. It is found in all malignant
elements, except teratoma. A recent tissue-based study sug-
gested miR-375 to be a potential biomarker for teratoma as
well.77
Recommendations
miR-371a-3p (and related family members) is an in-
vestigational biomarker to detect malignant TGCT com-
ponents, including the YST of the non-GCNIS variant
(type I) detectable both in tissue as well as body fluids (ie,
liquid biopsies).
CONCLUSIONS
A summary regarding the putative molecular biomarkers
of TGCTs is represented in Figure 1. These specifically relate
to the various types of TGCTs, being both variants in the





FIGURE 6. Illustrations of chromosomal anomalies (including 12p) as identified by karyotyping and FISH with a centromere—and
12p- specific probes (A). Results of chromosomal comparative genomic hybridization of GCNIS and various invasive components
(B), showing the specificity of gain of 12p for the latter. Also, spectral karyotyping (SKY) of a tumor metaphase spread is shown (C),
and an example of CNV (based) based on EPIC methylation profiling is demonstrated (D).71,72
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informative to distinct the types besides histologic composition,
specifically, gain of chromosome 12 for the invasive GCNIS-
related components and gain of chromosome 9 for the sper-
matocytic tumors. Aneuploidy and loss of 6q in the prepubertal
YST, in contrast to the prepubertal teratoma, is informative,
while all GCNIS-related teratomas are aneuploid and contain
gain of 12p. The methylation, as well as mutational profiles, are
less informative, based on the possible overlap as well as
(overall) low frequencies. Of particular interest is the miR-371a-
3p, found to be highly informative for all malignant (T)GCT
components, both in pediatric and (young) adult patients,
suitable to be used as liquid-biopsy based molecular biomarker.
It is expected that it will change the clinical handling of patients
with GCTs of the testis as well as other anatomic localization
(extracranial and cranial) drastically within the coming years
(Table 2).
It is evident that there has been tremendous progress
in the understanding of molecular genetics and biology of
TGCTs; however, only limited applications have been
translated to patient care currently. This lag is most likely
related to the rarity of TGCTS and their overall excellent
prognosis. In that context, future evaluation might be
more informative to be dedicated to specialized centers of
diagnosis and treatment. It is challenging to incorporate
much of the recently acquired knowledge into the clinical
practice, which further emphasizes that much more effort
is required to develop clinically relevant and cost-effective
assays.
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